Approval Record: VOBRIG — SUN PHARMACEUTICAL INDUSTRIES LIMITED, ORIG (Not disclosed in the FDA record.)

Key facts

What was approved

FDA's record shows SUN PHARMACEUTICAL INDUSTRIES LIMITED as the sponsor of VOBRIG, with the generic name recorded as unspecified and dosage form INJECTABLE. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. This specific application is submission type ORIG (submission number 1) under application number NDA213225, with a submission status date of 20260826. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

SUN PHARMACEUTICAL INDUSTRIES LIMITED’s FDA history

Argus HQ has recorded 1 total FDA action tied to SUN PHARMACEUTICAL INDUSTRIES LIMITED: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

Does SUN PHARMACEUTICAL INDUSTRIES LIMITED have other FDA approval records?

This is the only FDA action Argus HQ has on file for SUN PHARMACEUTICAL INDUSTRIES LIMITED so far. Argus ingests new FDA records daily.

What is the FDA application number for this submission?

FDA application number NDA213225, submission 1.

What review priority did FDA assign?

FDA designated this submission as: STANDARD.

What dosage form is VOBRIG?

VOBRIG is formulated as: INJECTABLE.

Related enforcement actions

• Approval (recent): MACLEODS PHARMS LTD — ANDA approval: SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (unspecified) →
• Approval (recent): SPIL — ANDA approval: POMALIDOMIDE (unspecified) →
• Approval (recent): QILU PHARM HAINAN — ANDA approval: DIFELIKEFALIN ACETATE (unspecified) →
• Approval (recent): DR REDDYS — ANDA approval: POMALIDOMIDE (unspecified) →
• Approval (recent): NATCO — ANDA approval: EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE (unspecified) →
• Approval (recent): GILEAD SCIENCES INC — NDA approval: Unspecified (unspecified) →
• Approval (recent): GILEAD SCIENCES — NDA approval: BIXLENVO (unspecified) →
• Approval (recent): ORBICULAR PHARM TECH — ANDA approval: NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE (unspecified) →